



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, **Indore** - 452001 (M.P.)

Tel. : (0731) 2517677 | **E-mail :** beryldrugs25@yahoo.com | **CIN :** L02423MP1993PLC007840

Date: 28.05.2026

To,
The DCS-Listing
The Bombay Stock Exchange Limited,
Phiroze JeeJeebhoy Towers,
Dalal Street, Mumbai – 400 001

Sub: SUBMISSION OF AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED 31ST MARCH, 2026 UNDER REGULATION 33 OF THE SECURITIES & EXCHANGE BOARD OF INDIA (LISTING OBLIGATION & DISCLOSURE REQUIREMENTS) REGULATION, 2015

Sir/ Madam,

Dear Sir(s), Pursuant to regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, in this connection, we are pleased to enclose the following: -

A. Statement of Audited Financial Results for the quarter and year ended 31st March, 2026, Statement of Assets and Liabilities and Cash Flow Statement.

B. Independent Auditor's Report on Audited Annual Financial Results for the quarter and year ended 31st March, 2026 by the Statutory Auditor M/s Subhash Chand Jain Anurag & Associates Chartered Accountants.

C. Declaration in respect of statement of impact of audit qualifications.


Kindly take on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited

Sudhir Sethi
Chairman & Director
DIN: 00090172



Subhash Chand Jain Anurag & Associates

Chartered Accountants

104, Archana Apartment, 8-B, Ratlam Kothi, Indore - 452001 (M.P.)

Ph: 2519439, 2527682

Mob No: +91-93021-23882

Email: scjainca2004@yahoo.com



Independent Auditors' Report on the Quarterly and Year to date Audited IND AS Financial Results of Beryl Drugs Limited pursuant to the Regulation 33 and Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

**To,
The Board of Directors,
Beryl Drugs Limited**

Report on the audit of the Ind AS Financial Results

Opinion

We have audited the accompanying statement of quarterly and year to date Ind AS financial results of Beryl Drugs Limited (the "Company") for the quarter and year ended 31 March 2026, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 and Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid annual financial results:

- are presented in accordance with the requirements of Regulation 33 and Regulation 52(4) of the Listing Regulations.
- give a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2026.



Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the IND AS Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the Ind AS financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

1. We draw attention to **Note 9** of the IND AS Financial Result for the Quarter and Year ended on 31st March 2026, which describes that, The Company has not recognized any liability in respect of professional tax pertaining to employees, as it has not obtained the necessary registration. Consequently, there may be a potential liability that remains unrecorded
2. We draw attention to **Note 10** of the IND AS Financial Result for the Quarter and Year ended on 31st March 2026, which describes that, The Office of the Controller, Food and Drugs Administration, Madhya Pradesh, vide their Order directed the Company to stop manufacturing activities in the Blow Fill Seal (BFS) Section w.e.f. 20/01/2025.

Consequently, the Company suspended production operations in the BFS Section with effect from February 2025, which adversely impacted the Revenue from Operations for the year ended 31st March 2026 as compared to the previous year.

Upon completion of rectification measures and submission of compliance, the aforesaid stop manufacturing order was revoked by the State Licensing Authority, Food and Drugs Administration, Madhya Pradesh, vide their Order dated 28.11.2025.

3. We draw attention to **Note 11** of the IND AS Financial Result for the Quarter and Year ended on 31st March 2026. The Company has adopted Ind AS 116 – Leases with effect from 1st April 2024 in respect of its long-term leasehold land arrangements (Plots 122, 123 and 124 situated at Pithampur, District Dhar), which were hitherto accounted for as "Leasehold Land" under Ind AS 16. On transition, the Company has applied the modified retrospective approach permitted under paragraph C5(b) of Ind AS 116 and has recognised the cumulative effect of initial application, amounting to ₹0.03 Lakhs, as an adjustment to the opening balance of Retained Earnings as at 1st April 2024.

Consequent to the above, the Company has recognised a Right-of-Use asset of ₹27.75 Lakhs and a Lease Liability of ₹4.95 Lakhs as at 31st March 2026. The Balance Sheet accordingly presents the financial position as at 1st April 2024 as the opening position for the comparative period.



Our opinion is not modified in respect of this matter.

Management's Responsibilities for the IND AS Financial Results

The Statement has been prepared on the basis of the IND AS annual financial statements.

The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other comprehensive income of the Company and other financial information in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.


In preparing the Statement, the Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the IND AS Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:



- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls with reference to Ind AS financial statements in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matters

1. As described in Note No. 03 of the Financial Results, The figures for the quarter ended March 31, 2026 are balancing figures between audited figures in respect of full financial year ended March 31, 2026 and the unaudited published figure upto December 31, 2025 being the end of third quarter of the financial year which were subjected to limited review by us.

Our report is not modified in respect of these matters.

2. The annual financial results dealt with by this report has been prepared for the express purpose of filing with the stock exchange. These results are based on and should be read with the audited financial statements of the company for the year ended March 31, 2026 on which we issued an unmodified opinion vide our report dated May 28, 2026.

For Subhash Chand Jain Anurag & Associates
Chartered Accountants

FRN-004733C



Akshay Jain

(Akshay Jain)

Partner

M. No. 447487

UDIN: 26447487LOMIBH6909

Date: 28/05/2026

Place: Indore



BERYL DRUGS LIMITED
Gr. Floor, 133, Kanchan Bagh, Indore (M.P.) – 452 001.
Tel./ Fax 0731-2517677
E-mail : beryldrugs25@yahoo.com
CIN : L02423MP1993PLC007840

ANNEXURE I

Part I Submission of Audited Financial Result by Companies Other than Banks

Statement of Audited Result for the Quarter/ year ended 31/03/2026

(Rs in lakhs)

S.No.	Particulars	Quarter ended			Year Ended	
		3 months ended (31-03-2026)	Preceding 3 months ended (31-12-2025)	Corresponding 3 months ended in the previous year (31-03-2025)	Year to date figures for current period ended (31-03-2026)	Year to date figures for previous period ended (31-03-2025)
		Audited	Unaudited	Audited	Audited	Audited
1	Revenue From Operations					
	Net sales or Revenue from Operations					
	Other operating revenues	512.91	377.68	397.36	1882.02	2114.62
	Total Revenue from operations (net)	33.83	7.36	124.60	49.00	140.86
2	Expenses	546.74	385.04	521.96	1931.02	2255.48
(a)	Cost of materials consumed					
(b)	Purchases of stock-in-trade	343.03	208.19	246.48	1050.99	1112.14
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00
(d)	Employee benefit expense	-30.69	-4.53	35.25	-74.32	-33.70
(e)	Finance costs	62.90	78.91	59.44	252.88	221.22
(f)	Depreciation and amortisation expense	7.15	9.17	7.90	34.43	53.42
(g)	Other Expenses	40.26	31.83	31.65	149.32	125.74
	Total expenses	37.51	122.25	131.05	458.92	691.23
3	Profit (loss) from operations before exceptional items and tax	460.16	445.82	511.77	1872.22	2170.05
4	Exceptional Items	86.58	-60.78	10.19	58.80	85.43
5	Profit (loss) before tax	0.00	0.00	0.00	0.00	0.00
6	Tax Expense	86.58	-60.78	10.19	58.80	85.43
	Current tax					
	Adjustments in respect of current income tax of prior years	3.43	-18.40	-14.58	10.69	20.11
	Deferred tax	0.00	0.01	0.00	0.69	-1.09
		26.90	-25.62	9.58	4.94	9.66
	Total Tax Expenses	30.33	-44.01	-5.00	16.32	28.68
7	Net Profit (loss) for the period from continuing operations	56.25	-16.77	15.19	42.48	56.75
8	Net Profit (loss) from discontinuing operations before tax	0.00	0.00	0.00	0.00	0.00
9	Tax Expense of discontinuing operations	0.00	0.00	0.00	0.00	0.00
10	Net Profit (loss) from discontinuing operations after tax	0.00	0.00	0.00	0.00	0.00
11	Net Profit (loss) for the Period	56.25	-16.77	15.19	42.48	56.75
12	Other comprehensive income					
(i)	Items that will not be reclassified to Statement of Profit and Loss					
(ii)	Items that will be reclassified to Statement of Profit and Loss	-2.11	6.83	-0.62	-1.81	0.16
13	Total Comprehensive Income	0.00	0.00	0.00	0.00	0.00
14	Details of equity share capital	54.14	-9.94	14.57	40.67	85.70
	Paid-up equity share capital					
	Face value of equity share capital	507.17	507.17	507.17	507.17	507.17
15	Earnings per share	10.00	10.00	10.00	10.00	10.00
i	Basic earnings per share before extraordinary items					
ii	Diluted earnings per share before extraordinary items	1.11	-0.33	0.30	0.84	1.12
		1.11	-0.33	0.30	0.84	1.12



Notes to the Results:

- 1 The above Financial Results for the quarter and year ended 31st March 2026 have been reviewed by the Audit Committee and approved & taken on record by the Board at their Board meeting held on Thursday, 28th May 2026 and the financial result have been audited by the Statutory Auditors of the Company. The statutory Auditors have expressed an unmodified audit opinion on the results.
- 2 This Statement is as per the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. These audited financial results of the Company are prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 (The Act) read with relevant Rules issued thereunder (Ind AS) and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India (SEBI).
- 3 The Statement includes the results for the Quarter ended 31 March 2026 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review.
- 4 Figures for the previous periods have been regrouped & recasted wherever necessary and minus figures are shown in brackets.
- 5 Depreciation on fixed assets is provided on written down value method as per the estimated remaining useful life of assets.
- 6 Revenue from Operations is net of GST & other deductions by customer.
- 7 Earnings per share amount is shown in Rupees.
- 8 The Company has identified "Pharmaceutical Industry" as the single operating segment for the continued operations in the standalone financial statements as per Ind AS 108 "Operating Segments".
- 9 The Company has not recognized any liability in respect of professional tax pertaining to employees, as it has not obtained the necessary registration. Consequently, there may be a potential liability that remains unrecorded.
- 10 The Office of the Controller, Food and Drugs Administration, Madhya Pradesh, vide their Order directed the Company to stop manufacturing activities in the Blow Fill Seal (BFS) Section w.e.f. 20/01/2025.

Consequently, the Company suspended production operations in the BFS Section with effect from February 2025, which adversely impacted the Revenue from Operations for the year ended 31st March 2026 as compared to the previous year.

Upon completion of rectification measures and submission of compliance, the aforesaid stop manufacturing order was revoked by the State Licensing Authority, Food and Drugs Administration, Madhya Pradesh, vide their Order dated 28.11.2025.


- 11 The Company has adopted Ind AS 116 - Leases with effect from 1st April 2024 in respect of its long-term leasehold land arrangements (Plots 122, 123 and 124 situated at Pithampur, District Dhar), which were hitherto accounted for as "Leasehold Land" under Ind AS 16. On transition, the Company has applied the modified retrospective approach permitted under paragraph C5(b) of Ind AS 116 and has recognised the cumulative effect of initial application, amounting to ₹0.03 Lakhs, as an adjustment to the opening balance of Retained Earnings as at 1st April 2024.

Consequent to the above, the Company has recognised a Right-of-Use asset of ₹27.75 Lakhs and a Lease Liability of ₹4.95 Lakhs as at 31st March 2026. The Balance Sheet accordingly presents the financial position as at 1st April 2024 as the opening position for the comparative period.

Date: 28th May 2026
Place: Indore

For and on behalf of the Board of Directors of
BERYL DRUGS LIMITED


Sanjay Sethi
Managing Director
DIN 00090277



Beryl Drugs Limited

CIN : L02423MP1993PLC007840

Registered Office : 133, Kanchan Bagh Colony, Indore (M.P.)-452001


Statement of Cash Flow for the year ended 31st March 2026

S.No. Particulars	For the year ended 31st March 2026	(Amount in Lakhs) For the year ended 31st March 2025
A Cash Flow from Operating Activities		
1 Profit Before Tax	58.80	85.43
Add : Depreciation, Amortization and Impairment	149.32	125.74
Add : Finance Cost	34.43	53.42
Less : Rental Income	(13.37)	(13.37)
2 Operating Profit Before Working Capital Changes	229.18	251.22
3 Adjustment for : (Increase) / Decrease in Operating Assets		
Inventories	(122.36)	(64.26)
Trade Receivables	336.88	212.68
Other Financial Assets	4.05	26.24
Other Non Current Assets	(42.83)	30.42
Other Current Assets	(47.68)	0.52
Increase/(Decrease) in Operating Liabilities and Provisions		
Provisions	9.92	7.45
Trade Payables	31.03	(90.05)
Other Financial Liabilities	(3.78)	(8.49)
Other Current Liabilities	(13.46)	(18.41)
4 Cash Flow used in Operations	23.70	(109.50)
Payment of Income Tax	380.94	347.33
Net Cash Used in Operating Activities (A)	(16.00)	(18.00)
	364.95	329.34
B Cash Flow from Investing Activities		
1 Purchase of Property Plant and Equipments (PPE)	(382.42)	(218.51)
2 Construction of godown held as Investment Property	(2.91)	-
3 Proceeds from Government Grant in respect of tangible assets	155.62	90.44
4 Rental Income	13.37	13.37
5 Bank Balances other than Cash & Cash Equivalents	-	9.82
Net Cash Used in Investing Activities (B)	(216.34)	(104.89)
C Cash Flow from Financing Activities		
1 Repayment of lease liabilities	(0.05)	(0.04)
2 Change of Short Term Borrowings	36.89	(36.22)
3 Proceeds from Long Term Borrowings	-	124.83
4 Repayment of Long Term Borrowings	(205.10)	(190.66)
5 Finance Costs	(34.43)	(53.42)
Net Cash Used in Financing Activities (C)	(202.69)	(155.50)
Net Increase/(Decrease) in Cash and Cash Equivalents (A to C)	(54.08)	68.94
Cash and Cash Equivalents at the Beginning of the Year	81.44	12.49
Cash and Cash Equivalents at the End of the Year	27.35	81.44
Components of Cash and Cash Equivalents:		
Cash on Hand	5.98	5.25
Balance with bank in Current Account	21.38	1.18
Fixed deposits with banks (original maturity less than 3 months)	-	75.00
	27.35	81.44

Notes :

- The above Statement of Cash Flows has been prepared under the indirect method set out in Ind AS-7 Statement of Cash Flows as specified in the Companies (Indian Accounting Standard), 2015.

For and on behalf of the Board of Directors
Beryl Drugs Limited
CIN: L02423MP1993PLC007840



Sanjay Sethi
Managing Director
DIN: 00090277

Date : 28/05/2026
Place : Indore

Beryl Drugs Limited


CIN : L02423MP1993PLC007840

Registered Office : 133, Kanchan Bagh Colony, Indore (M.P.)-452001

Balance Sheet as at 31st March 2026

S.No. Particulars	(Amount in Lakhs)		
	As at 31st March 2026	As at 31st March 2025	As at 01st April 2024 (Restated)
I) Asset			
A Non-Current Assets			
1 Property, Plant and Equipment	654.44	575.01	570.69
2 Right of Use Assets	27.75	28.93	30.11
2 Investment Property	21.73	19.59	20.38
3 Other Intangible assets	0.07	0.07	0.09
4 Financial assets			
a) Other Financial Assets	19.59	23.10	21.44
5 Deferred Tax Assets (Net)	-	0.61	10.33
6 Other Non-Current Assets	89.75	46.92	77.34
Total Non Current Assets	<u>813.33</u>	<u>694.24</u>	<u>730.37</u>
B Current Assets			
1 Inventories	312.64	190.28	126.02
2 Financial Assets			
a) Trade Receivable	208.83	545.71	758.39
b) Cash and cash equivalents	27.35	81.44	12.49
c) Bank balances other than (b) above	-	-	9.82
d) Other Financial Asstes	19.78	20.32	48.22
3 Other current assets	114.40	66.72	67.24
Total Current Assets	<u>683.00</u>	<u>904.46</u>	<u>1022.18</u>
Total Assets (A+B)	<u>1496.33</u>	<u>1598.69</u>	<u>1752.55</u>
II) Equity & Liabilities			
A Equity			
1 Equity Share Capital	509.37	509.37	509.37
2 Other Equity	479.38	438.71	381.80
Total Equity	<u>988.75</u>	<u>948.08</u>	<u>891.16</u>
B Non-Current Liabilities			
1 Financial Liabilities			
a) Borrowings	-	173.58	240.38
b) Lease Liability	4.90	4.95	4.99
2 Provisions	50.92	42.04	40.44
3 Deferred tax liabilities (Net)	3.69	-	-
Total Non-Current Liabilities	<u>59.51</u>	<u>220.56</u>	<u>285.81</u>
C Current Liabilities			
1 Financial Liabilities			
a) Borrowings	239.13	233.77	269.01
b) Lease Liability	0.05	0.05	0.04
c) Trade Payables	-	-	-
- total outstanding dues of micro enterprises and small enterprises	9.03	38.94	39.49
- total outstanding dues of creditors other than micro enterprises and small enterprises	133.55	72.61	162.12
d) Other Financial Liabilities	18.85	22.63	31.12
2 Other Current Liabilities	24.61	38.07	56.48
3 Provisions	15.46	11.97	6.34
4 Current Tax Liabilities (Net)	7.39	12.01	10.98
Total Current Liabilities	<u>448.07</u>	<u>430.05</u>	<u>575.58</u>
Total Liabilities and Equity (A to C)	<u>1496.33</u>	<u>1598.69</u>	<u>1752.55</u>

For and on behalf of the Board of Directors
Beryl Drugs Limited
CIN : L02423MP1993PLC007840



ate : 28/05/2026
lace : Indore

Sanjay Sethi
Managing Director
DIN : 00090277



BERYL DRUGS LIMITED

Regd. Off.: Ground Floor, 133, Kanchan Bagh, Indore - 452001 (M.P.)

Tel. : (0731) 2517677 | E-mail : beryldrugs25@yahoo.com | CIN : L02423MP1993PLC007840

28th May, 2026

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
MUMBAI – 400 001

Subject: Submission of declaration as per Second proviso to the Regulation 33(3)(d) of the SEBI (LODR) Regulation, 2015 for the Annual Audited Financial Results for the year ended 31st March, 2026.

Scrip Code: 524606

Dear Sirs,

We hereby submit the following declaration regarding unmodified Auditors Report on the Audited Financial Results/Statements for the year 31st March, 2026 as audited by the Auditors of the Company.

DECLARATION

Pursuant to the Regulation 33(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to SEBI (Listing obligation and Disclosure Requirements) Regulations, 2015, and amendments made therein vide SEBI Circular No SEBI/LAD-NRO/GN/2016-17 dated 25th May, 2016 and further amendment dated 27th May, 2016, We, the undersigned do hereby declare that in the Audit Report, accompanying the Annual Audited Financial Statements of M/s Beryl Drugs Limited for the financial year ended on 31.03.2026, the Auditor does not expressed any Modified Opinion(s)/ Audit Qualification(s)/ or other Reservation(s) and accordingly the the statement on impact of audit qualifications is not required to be given.

Kindly take the same on your record.

Thanking You,

Yours Faithfully,

For Beryl Drugs Limited

for Beryl Drugs Limited

Sanjay Sethi
Managing Director
DIN: 00090277



Ashish Baraskar
Chief Financial Officer